title: Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum.
abstract: Combined perfusion of the neostriatum with 1 nM of cholecystokinin octapeptide (CCK-8) and 0.01, 0.1 or 1 nM of neurotensin was done in the halothane-anesthetized rat after systemic apomorphine treatment (0.05 mg/kg, s.c.). Neurotensin (1 nM) plus CCK-8 (1 nM) effectively counteracted the apomorphine-induced inhibition of neostriatal perfusate levels of dopamine (DA). With a constant concentration of CCK-8 (1 nM), the apomorphine-induced inhibition of DA release was counteracted dose relatedly by neurotensin in concentrations of 0.01, 0.1 and 1 nM. The results of binding experiments demonstrated that threshold concentrations of CCK-8 and neurotensin significantly increased the KD values of the high-affinity D2 receptors without significant alterations in the low-affinity D2 receptors or in the proportion of D2 receptors in the high-affinity state. Thus, neurotensin and CCK receptors may regulate synergistically, via intramembrane interactions with the D2 receptors, the binding characteristics and the signal transduction of D2 autoreceptors in the neostriatum. The combined presence of very low concentrations of CCK-8 and neurotensin in the extracellular fluid may be sufficient to regulate D2 receptor transduction, underlining the important role of these peptide receptor interactions with the D2 receptors.
authors.affiliation: Department of Pharmacology, University of Ferrara, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Tanganelli
authors.forename: X M
authors.initials: XM
authors.lastname: Li
authors.forename: L
authors.initials: L
authors.lastname: Ferraro
authors.forename: G
authors.initials: G
authors.lastname: Von Euler
authors.forename: W T
authors.initials: WT
authors.lastname: O'Connor
authors.forename: C
authors.initials: C
authors.lastname: Bianchi
authors.forename: L
authors.initials: L
authors.lastname: Beani
authors.forename: K
authors.initials: K
authors.lastname: Fuxe
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D004347:Drug Interactions; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D009496:Neurotensin / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011949:Receptors, Cholecystokinin / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D012844:Sincalide / Q000494:pharmacology*
chemical_list: D011949:Receptors, Cholecystokinin; D017448:Receptors, Dopamine D2; D015102:3,4-Dihydroxyphenylacetic Acid; D009496:Neurotensin; D012844:Sincalide; D001058:Apomorphine; D004298:Dopamine; D006719:Homovanillic Acid